David S. Lamb

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

Anthony V. D’Amico, James W. Denham, Juanita Crook et al. · Journal of Clinical Oncology · 2007 · 499 citations · Full text

Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial

James W. Denham, Allison Steigler, David S. Lamb et al. · The Lancet Oncology · 2011 · 443 citations

Urology, Genitourinary Cancer, Medicine +6

Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial

James W. Denham, Allison Steigler, David S. Lamb et al. · The Lancet Oncology · 2005 · 376 citations

Urology, Radiation Medicine, Radiation Therapy +6

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial

James W. Denham, David Joseph, David S. Lamb et al. · The Lancet Oncology · 2014 · 159 citations

Zoledronic Acid, Urology, Trog 03.04 +6

Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase 3, factorial trial

James W. Denham, David Joseph, David S. Lamb et al. · The Lancet Oncology · 2018 · 105 citations

Zoledronic Acid, Urology, Radiation Medicine +7